ClexBio is a biotech company creating breakthrough solutions for tissue engineering and single-cell techniques by combining advanced microfluidics with our proprietary hydrogel technology CLEX.
ClexBio has raised €1.9M across 1 funding round from 5 investors, most recently a Seed round in Jul 2021. Based in Oslo, Norway; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-07-22 | Seed | €1.9M |
| Angel Investors,Centre for Digital Life Norway,Innovation Norway,Research Council of Norway,UK Engineering and Physical Sciences Research Council |
| View deal → |
